The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Effectiveness of adjuvant nivolumab across esophageal and GEJ cancers
Ronan Kelly, MD, MBA, Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, TX discusses the effectiveness of adjuvant nivolumab for the treatment of esophageal and gastroesophageal junction (GEJ) cancers. Results found patients with esophageal squamous cell carcinoma (ESCC) responded favorably to treatment, but efficacy was lower in patients with GEJ cancers. The availability of such peri-operative options is important when determining the best course of individualized patient care. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
